Grace Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common stock | ||||||
|---|---|---|---|---|---|---|
| (Expressed in thousands except share data) | Number | Amount | Additional paid-in capital | Accumulated other comprehensive loss | Accumulated deficit | Total stockholders' equity |
| Balance, March 31, 2026 | 16,024,026 | 1 | 298,413 | (6,038) | (228,480) | 63,896 |
| Issuance of common stock upon cashless exercise of pre-funded warrants | 250,000 | — | — | — | — | — |
| Net loss | — | — | — | — | (15,790) | (15,790) |
| Stock-based compensation | — | — | 105 | — | — | 105 |
| Balance at June 30, 2026 | 16,274,026 | 1 | 298,518 | (6,038) | (244,270) | 48,211 |
| Common stock | ||||||
|---|---|---|---|---|---|---|
| (Expressed in thousands except share data) | Number | Amount | Additional paid-in capital | Accumulated other comprehensive loss | Accumulated deficit | Total stockholders' equity |
| Balance, March 31, 2025 | 13,718,106 | 1 | 293,334 | (6,038) | (220,687) | 66,610 |
| Issuance of common stock upon cashless exercise of pre-funded warrants | 110,456 | — | — | — | — | — |
| Net loss | — | — | — | — | (3,362) | (3,362) |
| Stock-based compensation | — | — | 302 | — | — | 302 |
| Balance at June 30, 2025 | 13,828,562 | 1 | 293,636 | (6,038) | (224,049) | 63,550 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.